Product Description
Amfetamines are powerful psychostimulants, producing increased alertness, wakefulness, insomnia, energy and self-confidence in association with decreased fatigue and appetite as well as enhanced mood, well-being and euphoria. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/14871155/)
Mechanisms of Action: ADRA1A Agonist, ADRA2A Agonist, CYP2D6 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Canada | Chile | Israel | United Kingdom | United States
Approved Indications: None
Company: Takeda
Company Location: Asia Pacific
Company Founding Year: 1781
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Stress Disorders, Post-Traumatic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07664631 |
SMP | P1 |
Not yet recruiting |
Stress Disorders, Post-Traumatic |
2027-09-15 |
2026-06-25 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/06/2026 |
News Article |
Azurity Pharmaceuticals Announces the Availability of ARYNTA™ (lisdexamfetamine dimesylate) Oral Solution, CII |
|
02/10/2026 |
News Article |
Azurity Pharmaceuticals Announces ARYNTA™ (lisdexamfetamine dimesylate) Oral Solution, CII |
|
01/14/2026 |
News Article |
Top 10 Pet Poisons of 2025 |
|
11/20/2025 |
News Article |
RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties |